Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin.

Li D, Lee D, Dere RC, Zheng B, Yu SF, Fuh FK, Kozak KR, Chung S, Bumbaca Yadav D, Nazzal D, Danilenko D, Go MAT, Williams M, Polson AG, Poon KA, Prabhu S.

Br J Pharmacol. 2019 Oct;176(19):3805-3818. doi: 10.1111/bph.14784. Epub 2019 Aug 24.

2.

Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease.

Lichnog C, Klabunde S, Becker E, Fuh F, Tripal P, Atreya R, Klenske E, Erickson R, Chiu H, Reed C, Chung S, Neufert C, Atreya I, McBride J, Neurath MF, Zundler S.

Front Pharmacol. 2019 Feb 1;10:39. doi: 10.3389/fphar.2019.00039. eCollection 2019.

3.

Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease.

Tang MT, Keir ME, Erickson R, Stefanich EG, Fuh FK, Ramirez-Montagut T, McBride JM, Danilenko DM.

Aliment Pharmacol Ther. 2018 Jun;47(11):1440-1452. doi: 10.1111/apt.14631. Epub 2018 Mar 30. Review.

4.

Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis.

Wei X, Gibiansky L, Wang Y, Fuh F, Erickson R, O'Byrne S, Tang MT.

J Clin Pharmacol. 2018 Mar;58(3):386-398. doi: 10.1002/jcph.1031. Epub 2017 Nov 26.

5.

Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells.

Fuh FK, Looney C, Li D, Poon KA, Dere RC, Danilenko DM, McBride J, Reed C, Chung S, Zheng B, Mathews WR, Polson A, Prabhu S, Williams M.

Br J Pharmacol. 2017 Apr;174(8):628-640. doi: 10.1111/bph.13697. Epub 2017 Mar 6.

6.

Mass cytometry panel optimization through the designed distribution of signal interference.

Takahashi C, Au-Yeung A, Fuh F, Ramirez-Montagut T, Bolen C, Mathews W, O'Gorman WE.

Cytometry A. 2017 Jan;91(1):39-47. doi: 10.1002/cyto.a.22977. Epub 2016 Sep 15.

7.

DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.

Li D, Poon KA, Yu SF, Dere R, Go M, Lau J, Zheng B, Elkins K, Danilenko D, Kozak KR, Chan P, Chuh J, Shi X, Nazzal D, Fuh F, McBride J, Ramakrishnan V, de Tute R, Rawstron A, Jack AS, Deng R, Chu YW, Dornan D, Williams M, Ho W, Ebens A, Prabhu S, Polson AG.

Mol Cancer Ther. 2013 Jul;12(7):1255-65. doi: 10.1158/1535-7163.MCT-12-1173. Epub 2013 Apr 18.

8.

A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes.

Stefanich EG, Danilenko DM, Wang H, O'Byrne S, Erickson R, Gelzleichter T, Hiraragi H, Chiu H, Ivelja S, Jeet S, Gadkari S, Hwang O, Fuh F, Looney C, Howell K, Albert V, Balazs M, Refino C, Fong S, Iyer S, Williams M.

Br J Pharmacol. 2011 Apr;162(8):1855-70. doi: 10.1111/j.1476-5381.2011.01205.x.

9.

Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma.

Polson AG, Williams M, Gray AM, Fuji RN, Poon KA, McBride J, Raab H, Januario T, Go M, Lau J, Yu SF, Du C, Fuh F, Tan C, Wu Y, Liang WC, Prabhu S, Stephan JP, Hongo JA, Dere RC, Deng R, Cullen M, de Tute R, Bennett F, Rawstron A, Jack A, Ebens A.

Leukemia. 2010 Sep;24(9):1566-73. doi: 10.1038/leu.2010.141. Epub 2010 Jul 1.

PMID:
20596033
10.

In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates.

Zheng B, Fuji RN, Elkins K, Yu SF, Fuh FK, Chuh J, Tan C, Hongo JA, Raab H, Kozak KR, Williams M, McDorman E, Eaton D, Ebens A, Polson AG.

Mol Cancer Ther. 2009 Oct;8(10):2937-46. doi: 10.1158/1535-7163.MCT-09-0369. Epub 2009 Oct 6.

11.

CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.

Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y, Rice AG, van Abbema A, Wong M, Liu G, Zhan F, Dillon M, Chen S, Rhodes S, Fuh F, Tsurushita N, Kumar S, Vexler V, Shaughnessy JD Jr, Barlogie B, van Rhee F, Hussein M, Afar DE, Williams MB.

Clin Cancer Res. 2008 May 1;14(9):2775-84. doi: 10.1158/1078-0432.CCR-07-4246.

12.

Alpha beta T cell response to Toxoplasma gondii in previously unexposed individuals.

Subauste CS, Fuh F, de Waal Malefyt R, Remington JS.

J Immunol. 1998 Apr 1;160(7):3403-11.

13.

Role of CD80 (B7.1) and CD86 (B7.2) in the immune response to an intracellular pathogen.

Subauste CS, de Waal Malefyt R, Fuh F.

J Immunol. 1998 Feb 15;160(4):1831-40.

Supplemental Content

Support Center